Gilead Sciences (NASDAQ:GILD) announces the expiration of the HSR waiting period regarding its previously announced acquisition of Forty Seven (NASDAQ:FTSV) for ~$4.9B. The transaction should close in early April.
GILD is up 3% premarket on the advancement of remdesivir for the treatment of COVID-19.
https://seekingalpha.com/news/3556250-gilead-nearing-finish-line-on-forty-seven-buy
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.